Ignite Creation Date:
2025-12-25 @ 4:07 AM
Ignite Modification Date:
2025-12-26 @ 3:04 AM
Study NCT ID:
NCT00083720
Status:
COMPLETED
Last Update Posted:
2011-05-25
First Post:
2004-05-28
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Erbitux (Cetuximab) Given Alone to Patients With EGFR-Negative Metastatic Colon or Rectal Cancer That is Refractory to Chemotherapy
Sponsor:
Eli Lilly and Company
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2004-10
Start Date Type:
None
Primary Completion Date:
2008-04
Primary Completion Date Type:
ACTUAL
Completion Date:
2008-04
Completion Date Type:
ACTUAL
First Submit Date:
2004-05-28
First Submit QC Date:
None
Study First Post Date:
2004-06-02
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2009-04-16
Results First Submit QC Date:
None
Results First Post Date:
2009-10-23
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2011-05-19
Last Update Post Date:
2011-05-25
Last Update Post Date Type:
ESTIMATED